Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Launched by HUNAN PROVINCE TUMOR HOSPITAL · Mar 25, 2014

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called erlotinib combined with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to first-line treatments. The researchers believe that even after patients stop responding to initial treatments, they may still benefit from this combination therapy, particularly those with specific genetic changes in their cancer cells known as EGFR sensitive mutations. The goal is to see if this approach can help improve survival for these patients.

To participate in the trial, patients must be between the ages of 65 and 74, have advanced non-squamous NSCLC (stages IIIB or IV), and have already received treatment with a type of drug called a TKI but developed resistance to it. Participants will be monitored closely and may receive additional treatments during the study. It's important to note that those with certain conditions, such as unstable brain metastasis or spinal cord compression, may not be eligible. Overall, this trial is an opportunity for patients to potentially access new treatment options for their cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • advanced non-small cell lung cancer, stage IIIB/IV
• • non-squamous
• • EGFR sensitive mutations, such as exon 19 del, or exon 21 L858R
• • received first line TKIs treatment and developed TKI resistance
• • ECOG 0-2
• Exclusion Criteria:
• • squamous non-small cell lung cancer
• • patients have unstable brain metastasis, predict survival less than 8 weeks
• • spinal-cord compression without evidence of stabilisation or treatment
• • women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
• • patients have any unstable illness that could not receive further treatment